ADA Scientific Sessions 2025 Abstract

MET-233 Is an Ultra-Long-Acting Amylin Receptor Agonist

By James S. Minnion, Charlotte E. Hinds, Beata Reglinska

Experiments in animalsInterventions

The paper

James S. Minnion, Charlotte E. Hinds, Beata Reglinska

London

ADA Scientific Sessions 2025 Abstract, 13 Jun 2025

Presented at ADA Scientific Sessions 2025, poster 894-P

doi.org/10.2337/db25-894-p

Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
The New England Journal of Medicine4 Oct 2026
Retatrutide reduces weight and pain in adults with obesity
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes